We will perform a randomized clinical trial with minocycline. Minocycline is an antibiotic of
the tetracycline family and known to modulate inflammation, gelatinase activity and
angiogenesis, which we know are central mechanisms in CAA-pathology. Our aim is to prove in a
randomized clinical trial in a translational setting that minocycline treatment (duration 3
months) can decrease markers of neuroinflammation and the gelatinase pathway in the
cerebrospinal fluid (CSF) of persons with D-CAA (n=30) and sporadic-CAA (n=30).